The latest edition of STAT’s Health Tech newsletter brings you important dispatches from the J.P. Morgan Health Care ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A ...

Matthew Taylor, an analyst from Jefferies, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target remains ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...

In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Buy rating on Dexcom (DXCM – Research Report), with a ...

The sensor launched in August and can be used by any adult who doesn't take insulin. The report reflects Dexcom's effort to make Stelo more personalized and engaging for consumers as it works to ...

Adults in the US who want to measure their blood glucose levels using a wearable sensor will soon be able to buy one over-the-counter (OTC) for the first time. The FDA has cleared Dexcom’s Stelo ...

In March, the U.S. Food and Drug Administration cleared Stelo, a CGM option developed by DexCom for people not using insulin therapy. That includes many patients with type 2 diabetes and even ...

Stelo, the first over-the-counter glucose biosensor cleared2 by the FDA in the United States, is the first Dexcom product to use GenAI-enabled technology to produce weekly insights. The ...

Abbott and Dexcom have agreed to settle all of their remaining international legal disputes over patents related to their ...